Expanding ranges of advanced neurological and regenerative medicine have moved beyond simply “adding” cells to people. A more considered approach would be to look at the animals own biological environment where these cells will actually be delivered. As such, it is possible DFPP could be referred to as a type of pre-conditioning when included alongside selected UC-MSCs in PD support programs in the future.
Parkinson’s disease is usually thought of as big dopaminergic degeneration and α-synuclein aggregation (which, by the way, neurotoxic alpha-synuclein aggregates have direct impacts on pathways involved in metabolism) however modern scientific discussions define it more broadly as a systemic and multi-factorial neurodegenerative disorder with symptoms involving dysregulation of: 1) immune response or inflammation 2) mitochondrial dysfunction / bioenergetics / metabolic syndrome 3) protein-clearance impairment (due to loss-of-function mutations in genes/pathways that are important for autophagy / proteasomal degradation such as PRKN, PINK1), gut-brain axis dysbiosis.
Double filtration plasmapheresis (DFPP), a blood purification method that separates plasma and is used to isolate larger circulating elements. DFPP and related plasma filtration strategies have been discussed in literary works for their capacity to remove certain large-molecular-mass-solidity substances, including autoantibodies, immune complexes (ICs), lipoproteins and tumoral inflammatory mediators.
For Parkinsons Disease the idea is NOT DFPP is treating or reversing PD. One safe and scientifically valid explanation is that DFPP, performed before infusion of UC-MSCs, may downregulate a chosen systemic biological burden before reintroducing an element of regenerative support.
What Is DFPP?
A more selective technique of plasma filtration is double-filtration plasmapheresis. A blood processing system removes plasma and runs it through a second filter designed to strip out larger molecules of interest. DFPP is intended to be more selective than general plasma exchange since it seeks to remove specific plasma components, while retaining smaller, possibly more beneficial plasma proteins.
The study of DFPP primarily within the context of medical settings focused on disorders associated with pathological lipids, immune-mediated effects, inflammatory load and some autoimmune or neuroimmune conditions. Still, the use of a UC-MSCs injection for Parkinson’s disease beforehand should only be framed as an optimization model driven by biological plausibility and not established practice.
This distinction is important. Recognized biopsychosocial correlations This evidence is consistent with DFPP as a separation technique that may deplete proprietary circulating factors in certain diseases but does not provide confirmation that DFPP protects against less favorable outcomes following UC-MSCs injection for Parkinson’s disease.
Indications for DFPP Prior to Administration of UC-MSCs for Parkinson’s Disease
From this perspective above DFPP before UC-MSCs injection for Parkinson’s disease can be simply seen as a pre-conditioning step prior to regenerative support. Conversely, if there are high levels of inflammatory mediators, lipid-related particles, immune complexes or other circulating factors in the bloodstream then the internal signaling environment may not be as beneficial.
Parkinsons disease is more than a dopamine-depleting disorder. Systemic inflammation, neuroinflammation, mitochondrial dysfunction, oxidative stress, lipid metabolism, α-synuclein pathology gut–brain signaling and impairments of cellular clearance mechanisms are also mentioned recurrently at the forefront of research debate.
UC-MSCs are generally not thought of as straightforward “replacement cells” for damaged neurons. Less frequently associated effects are paracrine signalling, immune modulation, anti-inflammatory mediation and release of extracellular vesicles, cytokines, and growth-factor. Narrative reviews of MSC-based approaches in Parkinson’s emphasise the potential for neuroprotection, immunomodulation, trophic signalling and extracellular-vesicle mediated effects but continue to underline that clinical evidence is still developing.
This indicates that a clean, controllable environment may help UC-MSCs interact with our body in a better functional biological condition. In summary, this is the crux of the educational message: DFPP may act to prime biological soil prior to inoculating it with UC-MSCs.
Benefits of DFPP Prior to Injection of UC-MSCs for Parkinson Disease
Helps Reduce Selected Circulating Burden
The most obvious advantages of DFPP are the selective removal of components from the plasma. In the context of Parkinsons Disease support programs, this can be described as reducing unwanted circulating factors, and not using non-descriptive terms like detox.
Examples of these circulating factors could be certain inflammatory mediators, immune complexes, excess lipoproteins or large molecular weight plasma elements for their potential influence in systemic biological stress. This positions DFPP as a pre-treatment step for biological/biochemical preparation before UC-MSCs injection.
Provides a Balanced Inflammatory Environment
Both Neuroinflammation and systemic inflammation are being talked about as central components of the biology of Parkinsons disease. Prolonged inflammatory activity may lead to neuronal stress, α-synuclein-related pathology and progressive neurodegenerative processes.
DFPP may be a useful first stage intervention to lower certain inflammatory mediators in circulation and prepare for UC-MSCs Parkinson’s disease support.
DFPP does not halt Parkinson’s Progression What probably is a more accurate statement is that DFPP may indeed assist in perennial elimination of targeted inflammatory burden ahead of such regenerative cell-based support.
Potentially Improving the Biological “Terrain” Prior to UC-MSCs
One helpful way to explain this is the “soil and seed” illustration. You can think of UC-MSCs as the nutrient medium and your patient is the soil. On the other hand, if soil is overstuffed with inflammatory, immune, metabolic or oxidative stress then the reaction becomes more unpredictable.
DFPP may contribute to body preparation by decreasing some circulating interference. Since the UC-MSCs have an innate capacity to provide immune-balancing, anti-inflammatory and tissue-supportive signaling, they may then be injected into a potentially more permissive environment.
This concept is particularly important in the case of Parkinson’s disease because the disease encompasses complex interactions between the central nervous system, peripheral immune system, metabolic pathways and inflammatory signaling.
Figure A: Biological Preparation with DFPP Prior to UC-MSCs for Parkinson’s Disease
UC-MSCs Paracrine Role Complementary
They also have a beneficial paracrine activity, but are perhaps mostly studied as UC-MSCs. As such, their function is most frequently debated in terms of the release of signaling molecules rather than replacing lost dopaminergic neurons.
These signals are composed of extracellular vesicles, cytokines, growth factors and/or other bioactive molecules that can activate immune cells, vascular cells or tissue-repair pathways. Moreover, in the research field of Parkinsons disease, MSC-derived extracellular vesicles are also investigated as the therapeutic assets which is still emerging data.
This makes the context of the surrounding biological environment important. Thus, the greater reduction ability by DFPP on selected circulating inflammatory or lipid-related factors is plausibly in favor of creating a more supportive environment for UC-MSC paracrine signaling during or after CPAP.
Aids for a More Systematic Parkinson’s Disease Support Plan
DFPP can be used to construct a more systematic treatment path for going up the chain of premium neurological regenerative programs:
Before the treatmentNeurological assessment → DFPP biological preparation → UC-MSCs injection → Rehabilitation supportFollow-up and monitoring
This provides a more cosmetic outline for your system. The treatment is designed to be part of a medically guided Parkinson’s disease support scheme where UC-MSCs have not been given as an independent injection but rather considered in the perspective of inflammation, immune balance, metabolic burden, neurological function and together with rehabilitation and long-term monitoring.
A CONCEPT OF REGENERATIVE SUPPORT IN PARKINSON′ S DISEASE: DFPP + UC-MSCs
The hypothesis that earlier DFPP may enhance the effects of UC-MSCs is not directly due to a de-stabilize effect on the stem cells in itself. A more responsible explanation is:
First, DFPP may reduce some unwanted circulating factors. This may subsequently pose opportunities for UC-MSCs in being introduced to a more stable and homeostatic biological environment, where these immune regulatory, paracrine and anti-inflammatory signaling potentialities can be further stimulated.
Note: This wording is highly optimized, but also cautious medical wise.
This should be termed as supportive and investigational, not curative for Parkinson’s disease. Parkinsons remains an incurable neurodegenerative condition, and ‘normal’ neurology management with meds/rehab/specialised follow up is still paramount.
Important Medical Positioning
While both UC-MSCs Parkinson’s disease (PD) and DFPP prior to stem cell therapy are appealing regenerative medicine concepts, they should be carefully offered. As such the U.S. FDA informs us that regenerative medicine products, including but not limited to many of the stem cell and exosome products, are unapproved for neurological disorders and conditions, including not limited too Parkinson’s disease.
So the best positioning is not:
“DFPP Ensures Better Stem Cell Outcomes for Parkinsons Disease.
The better wording is:
Depending on these findings, some may consider DFPP as a pre-conditioning intervention to promote biological readiness prior to UC-MSCs injection in select patients with Parkinson’s disease bearing inflammatory, immune, lipid-related or metabolic burden.
Closing
An innovative and rationale strategy of stem cell therapy for advanced Parkinson’s disease in patients incorporating DFPP before UC-MSCs injection. DFPP may facilitate the readiness of the internal milieu for the UC-MSCs to enact their supportive, paracrine, immunomodulatory, and anti-inflammatory abilities by filtering specific variables from circulating factors prior to implementing cell-based support. Although outcomes may differ and more direct clinical evidence is lacking, this paradigm a strategy in many ways consistent with a contemporary concept of regenerative medicine should be interpreted as follows: when you determine new biological signals to add back into a system, first take steps to optimally prepare the environment that will need to respond to those signals.